Welcome to our dedicated page for Lifeloc Technologies news (Ticker: $LCTC), a resource for investors and traders seeking the latest updates and insights on Lifeloc Technologies stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Lifeloc Technologies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Lifeloc Technologies's position in the market.
Lifeloc Technologies (OTC Pink:LCTC), a global leader in breath alcohol and drug testing devices, reported its financial results for Q1 2024. The company posted a net revenue of $2.153 million, with a net loss of $284,000, or $0.12 per share, compared to a net loss of $54,000, or $0.02 per share, in Q1 2023. Gross margins fell to 38.8% from 43.2% due to increased costs driven by inflation. R&D investments surged by 40%, primarily focused on the SpinDx platform development. Despite financial challenges, the company is optimistic about its new products, including the smartphone-compatible LX9 units and the SpinDx technology for drug detection. SpinDx, which detects various drugs including delta-9-THC, is expected to start beta testing in late 2024, with commercialization projected for 2025.